{
    "Clinical Trial ID": "NCT00104650",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Bisphosphonate IV Q4W",
        "  Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)",
        "INTERVENTION 2: ",
        "  Denosumab 180 mg Q12W",
        "  Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients at least 18 years of age with histologically confirmed solid tumor carcinomas (except lung) or multiple myeloma",
        "  Radiographic evidence of 1 or more bone lesions or lytic lesion in myeloma",
        "  Currently receiving IV bisphosphonates",
        "  Urinary N-Telopeptide (uNTx) greater than 50 nM BCE/mM creatinine",
        "  Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2",
        "Exclusion Criteria:",
        "  More than 2 prior skeletal related events (SRE)",
        "  Known brain metastases",
        "  Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw",
        "  Active dental or jaw conditions which requires oral surgery",
        "  Non-healed dental/oral surgery",
        "  Prior administration of AMG 162",
        "  Evidence of impending fracture in weight bearing bones",
        "  Pregnancy or breastfeeding. Subjects must be surgically sterile, postmenopausal, or must agree to use effective contraception during the study."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13",
        "  Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13.",
        "  Time frame: 13 weeks",
        "Results 1: ",
        "  Arm/Group Title: Bisphosphonate IV Q4W",
        "  Arm/Group Description: Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  10",
        "Results 2: ",
        "  Arm/Group Title: Denosumab 180 mg Q12W",
        "  Arm/Group Description: Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)",
        "  Overall Number of Participants Analyzed: 33",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  21"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 19/35 (54.29%)",
        "  Anaemia 4/35 (11.43%)",
        "  Bone marrow failure 1/35 (2.86%)",
        "  Coagulopathy 0/35 (0.00%)",
        "  Leukopenia 2/35 (5.71%)",
        "  Neutropenia 2/35 (5.71%)",
        "  Thrombocytopenia 2/35 (5.71%)",
        "  Cardio-respiratory arrest 0/35 (0.00%)",
        "  Cardiopulmonary failure 2/35 (5.71%)",
        "  Pericardial effusion 0/35 (0.00%)",
        "  Sinus bradycardia 0/35 (0.00%)",
        "  Diplopia 0/35 (0.00%)",
        "Adverse Events 2:",
        "  Total: 16/35 (45.71%)",
        "  Anaemia 4/35 (11.43%)",
        "  Bone marrow failure 0/35 (0.00%)",
        "  Coagulopathy 0/35 (0.00%)",
        "  Leukopenia 0/35 (0.00%)",
        "  Neutropenia 2/35 (5.71%)",
        "  Thrombocytopenia 2/35 (5.71%)",
        "  Cardio-respiratory arrest 0/35 (0.00%)",
        "  Cardiopulmonary failure 0/35 (0.00%)",
        "  Pericardial effusion 1/35 (2.86%)",
        "  Sinus bradycardia 0/35 (0.00%)",
        "  Diplopia 0/35 (0.00%)"
    ]
}